Table 6.
Cancer | Liquid biomarker | Origin | Tendency | Downstream target | Function | Reference |
---|---|---|---|---|---|---|
HCC | miR-221-3p, miR-223-3p, miR-10b5p, miR-21-5p | Plasma exosome | up | Early diagnostic biomarker | 108 | |
LG3BP, PIGR | Serum exosome | up | Early diagnostic biomarker | 110 | ||
ECE1, HOXA1, cle11a, AK055957, PFKP, EMX1 methylation | Plasma | up | Early diagnostic biomarker | 112 | ||
cfDNA | Plasma | up |
Early diagnostic biomarker, Efficacy monitoring biomarker |
115 | ||
CTCs | Peripheral blood | up |
Early diagnostic biomarker, Tumor recurrence biomarker |
114 | ||
Mixed CTCs, Mesenchymal CTCs | Peripheral blood | up |
Early diagnostic biomarker, Disease progression biomarker |
116 | ||
CCA | microRNA-21, microRNA-221 | Plasma | up | Early diagnostic biomarker | 122 | |
hTERT, CK19 | Peripheral blood | up | Prognostic biomarker | 123 | ||
Osteopontin (OPN) | Serum | down | MMP1, MMP10, CXCR4 |
Efficacy monitoring biomarker, Prognostic biomarker |
124 | |
MMP-7 | Serum | up | Early diagnostic biomarker | 127 | ||
CYFRA 21-1 | Serum | up |
Early diagnostic biomarker, Disease progression biomarker |
129 | ||
Osteopontin (OPN) | Serum | up | Efficacy monitoring biomarker | 130 | ||
CTCs | Peripheral blood | up |
Tumor aggressiveness biomarker, Prognostic biomarker |
131 | ||
cfDNA mutation | Bile | up | Prognostic biomarker | 132 | ||
CRC | microRNA-203 | Serum exosome | up | M2-TAM | Prognostic biomarker | 135 |
microRNA-21 | Plasma exosome | up |
Tumor recurrence biomarker, Prognostic biomarker |
137 | ||
miR-17-5p, miR-92a-3p | Serum exosome | up |
Early diagnostic biomarker, Disease progression biomarker |
138 | ||
miR-25-3p | Serum exosome | up | Tumor aggressiveness biomarker | 139 | ||
miR-196b-5p | Serum exosome | up | STAT3 | Efficacy monitoring biomarker | 147 | |
miR-301a, miR-23a | Serum exosome | UP | Early diagnostic biomarker | 140 | ||
miR-19a | Serum exosome | up | Tumor recurrence biomarker | 142 | ||
QSOX1 | Serum exosome | down | Early diagnostic biomarker | 145 | ||
ctDNA | Plasma | up | Efficacy monitoring biomarker | 151 | ||
ctDNA | Plasma | up |
Tumor recurrence biomarker, Prognostic biomarker |
152 |